Author:
Yu Lio,Moloney Mairead,Zheng Songzhu,Rogers James
Abstract
Abstract
Background
To compare the effectiveness of high-resolution dermal ultrasound (US) guided superficial radiotherapy (SRT) to non-image-guided radiotherapy in the treatment of early-stage Non-Melanoma Skin Cancer (NMSC).
Methods
A high-resolution dermal ultrasound (US) image guided form of superficial radiation therapy (designated here as US-SRT) was developed in 2013 where the tumor configuration and depth can be visualized prior to, during, and subsequent to treatments, using a 22 megahertz (MHz) dermal ultrasound (US) with a doppler component. We previously published the results using this technology to treat 2917 early-stage epithelial cancers showing a high local control (LC) rate of 99.3%. We compared these results with similar American studies from a comprehensive literature search used in an article/guideline published by American Society of Radiation Oncology (ASTRO) on curative radiation treatment of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and squamous cell carcinoma in-situ (SCCIS) lesions from 1988 to 2018. Only U.S. based studies with greater than 100 cases with similar patient/lesion characteristics and stages treated by external beam, electron, or superficial/orthovoltage radiation therapy were included in the criteria for selection. The resultant 4 studies had appropriate comparable cases identified and the data analyzed/calculated with regard to local control. Logistic regression analysis was performed comparing each study to US-SRT individually and collectively with stratification by histology (BCC, SCC, and SCCIS).
Results
US-SRT LC was found to be statistically superior to each of the 4 non-image-guided radiation therapy studies individually and collectively (as well as stratified by histology subtype) with p-values ranging from p < 0.0001 to p = 0.0438.
Conclusions
Results of US-SRT in local control were statistically significantly superior across the board versus non-image-guided radiation modalities in treatment of epithelial NMSC and should be considered a new gold standard for treatment of early-stage cutaneous BCC, SCC, and SCCIS.
Funder
SkinCure Oncology
Next Step Business Services, LLC
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference18 articles.
1. "Cancer A-Z," 26 July 2019. [Online]. Available: https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer/about/what-is-basal-and-squamous-cell.html#references. [Accessed April 2022].
2. Rogers H, et al. Incidence estimate of nonmelanoma skin cancer (Kertinocute Carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081–6.
3. K.J. Buster, E.I. Stevens, and C.A.Elmets, "Dermatologic health disparities", Dermatol Clin., vol 30, no. 1, 2012. doi:https://doi.org/10.1016/j.det.2011.08.002.
4. Fahradyan A, et al. Updates on the Management of Non-Melanoma Skin Cancer (NMSC). Healthcare. 2017;5(4):1.
5. Alam M, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol (JAAD). 2018;78(3):560–78. https://doi.org/10.1016/j.jaad.2017.10.007, March.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献